Li Haiyan, Cao Wei
Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Hubei Province Key Laboratory of Molecular Imaging, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
J Thorac Dis. 2020 Jun;12(6):3217-3226. doi: 10.21037/jtd-19-4171.
Pulmonary enteric adenocarcinoma (PEAC) is an extremely rare type of non-small cell lung cancer (NSCLC) with a histologic pattern that mimics metastatic colorectal cancer (MCC). The main clinical symptoms in PEAC patients are dyspnoea, coughing, hemoptysis, and chest and back pain. The first article about PEAC appeared in 1991 in the form of a case report. As a variant of invasive lung carcinoma, only a small number of case reports and clinical research studies have been carried out, and the only one guidance on diagnosis and treatment is the WHO Tumor Classification book. It is important for doctors to distinguish PEAC from MCC to extend survival time and improve the quality of life. We reviewed the existing literature regarding the diagnosis, treatment, and prognosis of PEAC to provide some valuable clinical references.
肺肠型腺癌（PEAC）是一种极其罕见的非小细胞肺癌（NSCLC），其组织学模式类似于转移性结直肠癌（MCC）。PEAC患者的主要临床症状为呼吸困难、咳嗽、咯血以及胸背部疼痛。关于PEAC的第一篇文章于1991年以病例报告的形式发表。作为浸润性肺癌的一种变体，仅开展了少数病例报告和临床研究，唯一的诊断和治疗指南是世界卫生组织的《肿瘤分类》一书。对于医生而言，将PEAC与MCC区分开来对于延长生存时间和提高生活质量至关重要。我们回顾了有关PEAC诊断、治疗和预后的现有文献，以提供一些有价值的临床参考。
